These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 16098070)

  • 21. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
    Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
    Takahashi W; Arai Y; Tadokoro J; Takeuchi K; Yamagata T; Mitani K
    Rinsho Ketsueki; 2006 Feb; 47(2):111-4. PubMed ID: 16529013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
    Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

  • 32. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
    Matsumoto S; Kimura S; Segawa H; Kuroda J; Yuasa T; Sato K; Nogawa M; Tanaka F; Maekawa T; Wada H
    Lung Cancer; 2005 Jan; 47(1):31-9. PubMed ID: 15603852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
    Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
    Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia?
    Köchling J; Schmidt M; Rott Y; Sagner M; Ungefroren H; Wittig B; Henze G
    Eur J Haematol; 2013 Apr; 90(4):291-300. PubMed ID: 23294316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
    Kimura S; Kuroda J; Segawa H; Sato K; Nogawa M; Yuasa T; Ottmann OG; Maekawa T
    Int J Hematol; 2004 Jan; 79(1):37-43. PubMed ID: 14979476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529.
    Segawa H; Kimura S; Kuroda J; Sato K; Nogawa M; Yuasa T; Yokota A; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2005 Apr; 29(4):451-7. PubMed ID: 15725480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemia.
    McKenna SJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):137-9. PubMed ID: 10673646
    [No Abstract]   [Full Text] [Related]  

  • 40. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?
    Thomas X
    Lancet Oncol; 2015 Nov; 16(15):1451-1453. PubMed ID: 26432047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.